ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2828

A Graph-Theoretic-Approach Applied to Modular-Repertoire-Analysis Identifies Shared Gradual Whole Blood Interferon Signatures in Systemic Lupus Erythematosus and Primary Sjögren’s Syndrome Patients and Reveals New Interferon-Related Modules in Disease Progression

Ilya Korsunski1, Noémie Jourde-Chiche2, Peter Gregersen3, Damien Chaussabel4, Laurent Chiche5 and Naomi I. Maria6, 1Center for Genomics and Human Genetics, Feinstein Institute for Medical Research, Manhasset, NY, 2Nephrology, AP-HM, Department of Nephrology, CHU Conception, Marseille, France, 3Robert S. Boas Center for Genomics and Human Genetics, Feinstein Institute for Med Res, Manhasset, NY, 4Translational Medicine, Sidra Medical and Research Center, Doha, Qatar, 5Internal medicine, Hopital europeen, Marseille, France, 6Center for Autoimmune and Musculoskeletal Diseases, Feinstein Institute for Medical Research, Manhasset, NY

Meeting: 2017 ACR/ARHP Annual Meeting

Date of first publication: September 18, 2017

Keywords: Genetic Biomarkers, interferons, neutrophils and systemic lupus erythematosus (SLE), Sjogren's syndrome

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, November 7, 2017

Title: Genetics, Genomics and Proteomics

Session Type: ACR Concurrent Abstract Session

Session Time: 4:30PM-6:00PM

Background/Purpose: There is significant clinical and molecular heterogeneity among patients suffering from systemic autoimmune diseases, such as systemic lupus erythematosus (SLE) and primary Sjögren’s Syndrome (pSS). Deciphering this heterogeneity could allow the molecular stratification of patients in terms of prognosis and therapeutic targets. Our previous work using a modular repertoire analysis (MRA) has demonstrated that the IFN signature observed in SLE patients is not restricted to a mere type I IFN signature, but involves the gradual activation of 3 distinct IFN modules driven by various IFN types including IFNγ. Although a type I IFN signature has been described in patients with pSS, a detailed MRA in pSS is still lacking. Here we aimed to refine MRA and discover new transcriptional signatures in SLE and pSS, by applying a novel graph-theoretic-approach (GTA) to reveal the progression of module activation patterns in these diseases.

Methods: Blood transcriptomic microarray datasets, including that of SLE patients (n=157 samples; LUPUCE cohort) fulfilling ACR-criteria and pSS patients (n=133; UKPSSR) fulfilling American European Consensus Group (AECG)-criteria, were analyzed using MRA followed by GTA. MRA was performed using a blood modular framework comprising 260 modules. A novel GTA, based on the Extended Suppes Bayes Causal Network (ESBCN), was used to generate an ordered, branching progression model of modular activation. Disease-specific causal graphs in selected datasets were built in order to generate hypotheses regarding disease progression for a particular disease. Significance to clinical characteristics was evaluated using Fisher’s exact test and ANOVA, for categorical and continuous characteristics, respectively.

Results: The GTA-to-MRA analysis confirmed the previously described pattern of gradual activation of IFN modules in SLE patients: first M1.2 (81.5%), then M3.4 (67.5%) and finally M5.12 (22.3%). Interestingly, this gradual IFN signature was also observed in pSS patients who exhibited activation of 1 (64%), 2 (37%) or all 3 (8%) IFN modules. Additionally, GTA-to-MRA identified a dual mode of disease progression in SLE after the activation of the IFN modules M1.2 and M3.4: either completion of the IFN signature, to include the more IFNγ-related module M5.12 and with completion of a newly identified 4th IFN-related module M8.59, or the activation of a neutrophil module M5.15 associated with renal involvement. In pSS, a dual mode of progression identified comparable completion of IFN signature to include M5.12, ending with the new IFN module M8.59, or activation of a 5th IFN-related module M8.95. Solely 6% of pSS patients portrayed a neutrophil signature, not linked to IFN progression, possibly identifying a relevant new pSS subgroup.

Conclusion: The application of GTA to blood MRA reveals for the first time the sharing of gradual activation of IFN modules between SLE and pSS, identifies new IFN-related modules through the observation of progression patterns, and discerns a pattern of progression involving a neutrophil signature associated with renal involvement in patients with SLE. Defining distinct molecular subgroups will aid in development of more tailored therapeutic regimens.


Disclosure: I. Korsunski, None; N. Jourde-Chiche, None; P. Gregersen, None; D. Chaussabel, None; L. Chiche, None; N. I. Maria, None.

To cite this abstract in AMA style:

Korsunski I, Jourde-Chiche N, Gregersen P, Chaussabel D, Chiche L, Maria NI. A Graph-Theoretic-Approach Applied to Modular-Repertoire-Analysis Identifies Shared Gradual Whole Blood Interferon Signatures in Systemic Lupus Erythematosus and Primary Sjögren’s Syndrome Patients and Reveals New Interferon-Related Modules in Disease Progression [abstract]. Arthritis Rheumatol. 2017; 69 (suppl 10). https://acrabstracts.org/abstract/a-graph-theoretic-approach-applied-to-modular-repertoire-analysis-identifies-shared-gradual-whole-blood-interferon-signatures-in-systemic-lupus-erythematosus-and-primary-sjogrens-syndrome-pat/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2017 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/a-graph-theoretic-approach-applied-to-modular-repertoire-analysis-identifies-shared-gradual-whole-blood-interferon-signatures-in-systemic-lupus-erythematosus-and-primary-sjogrens-syndrome-pat/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology